News

The Pharma Letter2d
Illuminating neuromyelitis optica
Neuromyelitis optica spectrum disorder (NMOSD) – also known as neuromyelitis optica (NMO) and Devic’s disease – is a rare, ...
Physician's Weekly12d
Clinical Biomarkers for Assessing Disability in Acute NMOSD
The following is a summary of “Acute neuromyelitis optica spectrum disorder patients’ clinical analysis of disability-related ...
Managed Healthcare Executive2d
FDA Approves Uplizna for Chronic Inflammatory Condition IgG4-RD
Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition ...
Managed Healthcare Executive1d
Bkemv and Epysqli, Two Biosimilars of Soliris, are Now Available
Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...
pharmaphorum5d
Uplizna is first drug FDA-cleared for rare disease IgG4-RD
Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...
Medscape5d
FDA Approves First and Only Therapy for IgG4-RD
Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...
Stocktwits on MSN5d
Amgen Stock Edges Higher After Uplizna Becomes First FDA-Approved Treatment For Immune-Mediated Disorder – Retail Gets More Bullish
Shares of medicine manufacturer Amgen Inc (AMGN) are in the spotlight on Friday after it announced that the U.S. Food and ...
The American Journal of Managed Care6d
Inebilizumab FDA Approved as First Treatment for IgG4-RD
Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...
FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder
The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.